Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis

References

• Bang, Y.J., et al., 2017. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, 18 (12), 1637–1651.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, 2014. Lynparza summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003726/WC500180151.pdf [Accessed 30 May 2017].
   Google Scholar
• Evers, B., et al., 2008. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clinical Cancer Research, 14 (12), 3916–3925.
   PubMed Web of Science ®Google Scholar
• Fagotti, A., et al., 2020. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecological Cancer, 30 (11), 1657–1664.
   PubMed Web of Science ®Google Scholar
• Farmer, H., et al., 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434 (7035), 917–921.
   PubMed Web of Science ®Google Scholar
• FDA. 2014. Lynparza: highlights of prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf [Accessed 30 May 2017].
   Google Scholar
• Guo, X.X., et al., 2018. The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 10, 2553–2562.
   PubMed Web of Science ®Google Scholar
• Jelovac, D. and Armstrong, D.K., 2011. Recent progress in the diagnosis and treatment of ovarian cancer. Cancer, 61 (3), 183–203.
   Web of Science ®Google Scholar
• Kaye, S.B., et al., 2012. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology, 30 (4), 372–379.
   PubMed Web of Science ®Google Scholar
• Kujawa, K.A. and Lisowska, K.M., 2015. Ovarian cancer–from biology to clinic. Postepy higieny i medycyny doswiadczalnej, 69, 1275–1290.
   Web of Science ®Google Scholar
• Laganà, A.S., et al., 2015. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. European Journal of Gynaecological Oncology, 36 (5), 495–505.
   PubMed Web of Science ®Google Scholar
• Ledermann, J., et al., 2012. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. The New England Journal of Medicine, 366 (15), 1382–1392.
   PubMed Web of Science ®Google Scholar
• Ledermann, J., et al., 2014. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology., 15 (8), 852–861.
   PubMed Web of Science ®Google Scholar
• Moore, K., et al., 2018. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. The New England Journal of Medicine, 379 (26), 2495–2505.
   PubMed Web of Science ®Google Scholar
• Moya-Alarcón, C., et al., 2022. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: is it cost-effective in Spain? Gynecologic Oncology, 164 (2), 406–414.
   PubMed Web of Science ®Google Scholar
• Oza, A.M., et al., 2015. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. The Lancet-Oncology, 16 (1), 87–97.
   PubMed Web of Science ®Google Scholar
• Patel, A.G., Sarkaria, J.N. and Kaufmann, S.H., 2011. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proceedings of the National Academy of Sciences of the United States of America, 108 (8), 3406–3411.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine, E., et al., 2017. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 18 (9), 1274–1284.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard, I., PAOLA-1 Investigators, et al., 2019. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. The New England Journal of Medicine, 381 (25), 2416–2428.
   PubMed Web of Science ®Google Scholar
• Reinbolt, R.E. and Hays, J.L., 2013. The role of PARP inhibitors in the treatment of gynecologic malignancies. Frontiers in Oncology, 3, 237.
   PubMedGoogle Scholar
• Robson M., 2017. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine., 377 (17), 1700.
   Web of Science ®Google Scholar
• Rottenberg, S., et al., 2008. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of National Academy of Science USA, 105 (44), 1707–1984.
   Web of Science ®Google Scholar
• Shah, P.D., et al., 2021. Combination ATR and PARP Inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic Oncology, 163 (2), 246–253.
   PubMed Web of Science ®Google Scholar
• Siegel, R.L., et al., 2022. Cancer statistics, 2022. Cancer, 72 (1), 7–33.
   Web of Science ®Google Scholar
• Sung, H., et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Carcinoma, 71 (3), 209–249.
   Web of Science ®Google Scholar
• Wang, J., et al., 2022. Integrated analysis of prognostic immune-related genes in the tumor microenvironment of ovarian cancer. Annals of Translational Medicine, 10 (2), 91.
   PubMed Web of Science ®Google Scholar
• Zheng, F., et al., 2020. Mechanism and current progress of poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomedecine & Pharmacotherapie [Biomedicine & Pharmacotherapy], 123, 109661.
   PubMed Web of Science ®Google Scholar